Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Taro Yamashita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3383-9131; OpenAlex author ID A5057744038, A5125549341. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
67
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 6 papers · 2026: 4 papers

Papers 20

  1. Ovarian cancer mimicking pancreatic cancer. Last author DOI 10.1007/s10396-026-01684-y↗
  2. Pilot validation of a whole-blood mRNA expression-based diagnostic system for early-stage pancreatic ductal adenocarcinoma: a single-center case-control diagno… Last author DOI 10.1038/s41598-026-58684-8↗
  3. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  4. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  5. Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer. Last author DOI 10.1002/1878-0261.13796↗
  6. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  7. Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s44276-024-00116-z↗
  8. Elusive Diagnosis: Liver Tumor Emerging After Early Pancreatic Cancer Surgery. Last author DOI 10.1053/j.gastro.2025.02.009↗
  9. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  10. Metachronous Pancreatic Cancer with Pancreaticobiliary Maljunction Diagnosed Five Years after Cholecystectomy for Gallbladder Cancer, in Which Follow-up Imagin… Last author DOI 10.2169/internalmedicine.4581-24↗
  11. Gastrointestinal: Relapsed Type 1 autoimmune pancreatitis mimicking pancreatic cancer. Last author DOI 10.1111/jgh.16582↗
  12. Pancreatic Juice Cytology Evaluations Using Synthetic Secretin and Serial Pancreatic Juice Aspiration Cytological Examination for the Diagnosis of Pancreatic D… Co-author DOI 10.3390/diagnostics13091536↗
  13. Efficacy of a novel self-expandable metal stent with dumbbell-shaped flare ends for distal biliary obstruction due to unresectable pancreatic cancer. Co-author DOI 10.1038/s41598-022-25186-2↗
  14. Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.jcyt.2020.08.001↗
  15. Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. Co-author PMID 34249452↗
  16. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer … Co-author DOI 10.1136/jitc-2020-001367↗
  17. Oligopeptide Transporter-1 is Associated with Fluorescence Intensity of 5-Aminolevulinic Acid-Based Photodynamic Diagnosis in Pancreatic Cancer Cells. Co-author DOI 10.33160/yam.2020.08.003↗
  18. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. Co-author DOI 10.1111/cas.13944↗
  19. Development of novel diagnostic system for pancreatic cancer, including early stages, measuring mRNA of whole blood cells. Co-author DOI 10.1111/cas.13971↗
  20. Efficacy and safety of pancreatic juice cytology by using synthetic secretin in the diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/den.13203↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akihiro Seki · 5 shared papers, 2020–2026 · strength 1.04
  2. Masaki Miyazawa · 5 shared papers, 2019–2026 · strength 0.90
  3. Yoshio Sakai · 7 shared papers, 2019–2025 · strength 0.85
  4. Shuichi Kaneko · 5 shared papers, 2019–2025 · strength 0.62
  5. Akihiko Kida · 2 shared papers, 2024–2026 · strength 0.61
  6. Makoto Ueno · 3 shared papers, 2025–2026 · strength 0.60
  7. Takeshi Terashima · 4 shared papers, 2019–2025 · strength 0.57
  8. Yohei Takeda · 4 shared papers, 2018–2026 · strength 0.56
  9. Hajime Isomoto · 4 shared papers, 2018–2026 · strength 0.56
  10. Alessandro Nasti · 4 shared papers, 2019–2025 · strength 0.49
  11. Tuyen Thuy Bich Ho · 3 shared papers, 2019–2025 · strength 0.42
  12. Kouki Morita · 1 shared paper, 2025 · strength 0.42
  13. Kazuo Hara · 2 shared papers, 2026 · strength 0.41
  14. Kazuyoshi Ohkawa · 2 shared papers, 2026 · strength 0.41
  15. Yoshito Komatsu · 2 shared papers, 2025–2026 · strength 0.40
  16. Masafumi Ikeda · 2 shared papers, 2025–2026 · strength 0.40
  17. Masato Ozaka · 2 shared papers, 2025–2026 · strength 0.40
  18. Junji Furuse · 2 shared papers, 2025–2026 · strength 0.40
  19. Takafumi Nakagawa · 1 shared paper, 2026 · strength 0.39
  20. Takumi Onoyama · 3 shared papers, 2018–2023 · strength 0.35
  21. Kazuya Matsumoto · 2 shared papers, 2018–2023 · strength 0.24
  22. Masahisa Kobayashi · 1 shared paper, 2024 · strength 0.23
  23. Shuichi Kaneko · 2 shared papers, 2021 · strength 0.22
  24. Kenji Ikezawa · 1 shared paper, 2026 · strength 0.20
  25. Susumu Hijioka · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.